Detalhe da pesquisa
1.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 783-794, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381664
2.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
N Engl J Med
; 375(16): 1532-1543, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641143
3.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet
; 390(10102): 1585-1594, 2017 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28755782
4.
New therapies for gout.
Annu Rev Med
; 64: 325-37, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23327525
5.
Romosozumab Treatment in Postmenopausal Osteoporosis.
N Engl J Med
; 376(4): 396-7, 2017 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28121504
6.
The crystallization of monosodium urate.
Curr Rheumatol Rep
; 16(2): 400, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24357445
7.
Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street.
South Med J
; 107(4): 235-41, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24937517
8.
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 10(10): 1198-1208, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34302449
9.
Predictors of imminent risk of fracture in Medicare-enrolled men and women.
Arch Osteoporos
; 15(1): 120, 2020 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32748034
10.
Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
Medicine (Baltimore)
; 99(35): e21675, 2020 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871882
11.
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
J Bone Miner Res
; 35(7): 1333-1342, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445228
12.
Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout.
Can J Cardiol
; 36(11): 1722-1728, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32454073
13.
Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.
Bone
; 134: 115287, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092479
14.
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Bull Hosp Jt Dis (2013)
; 77(2): 87-91, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31140959
15.
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Arch Osteoporos
; 14(1): 59, 2019 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168657
16.
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.
J Bone Miner Res
; 33(8): 1407-1416, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750828
17.
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
J Bone Miner Res
; 33(7): 1219-1226, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573473
18.
A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care.
J Am Geriatr Soc
; 65(8): 1829-1835, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28422273
19.
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Bone
; 103: 209-215, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687496
20.
A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
Clin Ther
; 39(7): 1276-1290, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28629610